David Michael Leone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Michael Leone has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Reuben Opotowsky
Adult Congenital Heart Disease Program, Heart Institute, Cincinnati Children's Hospital Medical Center
3 shared publications Alexander R. Opotowsky
2 shared publications- Renaud David
Department of Child and Adolescent Health, Division of Pediatrics III—Cardiology, Pulmonology, Allergology and Cystic Fibrosis, Medical University of Innsbruck, 6020 Innsbruck, Austria
2 shared publications - Rohith Vanam
Heart Institute (N.A.K., D.M.L., R.V., J. Theobald, J.B.A., A.R.O.)
2 shared publications - Roni M. Jacobsen
Children’s Hospital of Colorado
2 shared publications - Sarah A. Hummel
Pediatrics (D.M.L., R.V., J. Theobald, S.A.H., J.B.A., A.R.O.), Cincinnati Children's Hospital Medical Center, OH (J.B.A. now with Pediatrics, UNC Health, Chapel Hill, NC)
2 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 221
Natural language processing to build a computable phenotype library for adults with congenital heart disease
- 19 August 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 221
Open AccessNatural language processing to build a computable phenotype library for adults with congenital heart disease
- Open Access
- 18 August 2026
- Published by Elsevier in JTCVS Open
Predictors of right heart failure after continuous-flow left ventricular assist device implantation in children: A machine learning analysis
- 18 August 2026
- Published by Elsevier in JTCVS Open
Open AccessPredictors of right heart failure after continuous-flow left ventricular assist device implantation in children: A machine learning analysis
- 12 August 2026
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 38 (5) , 461-468
The electrocardiogram and artificial intelligence: turning signals into insights in pediatric and congenital heart disease
Purpose of review: Artificial intelligence applied to electrocardiography (AI-ECG) has rapidly been investigated in adult cardiovascular medicine, yet translation into pediatric and congenital heart disease populations has lagged. This review summarizes contemporary AI-ECG methodologies and emerging applications in pediatric and congenital heart disease (PCHD), with emphasis on current clinical utility, technical challenges, and future opportunities for implementation. Recent findings: Recent studies demonstrate that deep learning models can accurately identify arrhythmias, ventricular dysfunction, and CHD from standard ECG. Convolutional neural networks remain the dominant architecture, although transformer-based foundation models and self-supervised learning approaches are increasingly being explored. AI-ECG applications in PCHD have expanded from automated interpretation toward proactive risk stratification, including prediction of ventricular dysfunction, mortality, and sudden cardiac death risk. Additional work has investigated wearable monitoring, telemetry analysis, and integration with longitudinal clinical data. Despite promising performance, most studies remain retrospective and single-center, with limited external validation and challenges related to small datasets, physiologic heterogeneity, and age-dependent ECG variation. Summary: AI-ECG has the potential to transform PCHD by improving diagnostic accuracy, enabling earlier disease detection, and enhancing longitudinal risk assessment. Broader clinical implementation will require multicenter collaboration, prospective validation, standardized datasets, and careful attention to ethical, regulatory, and equity considerations.
- 12 August 2026
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 38 (5) , 461-468
The electrocardiogram and artificial intelligence: turning signals into insights in pediatric and congenital heart disease
Purpose of review: Artificial intelligence applied to electrocardiography (AI-ECG) has rapidly been investigated in adult cardiovascular medicine, yet translation into pediatric and congenital heart disease populations has lagged. This review summarizes contemporary AI-ECG methodologies and emerging applications in pediatric and congenital heart disease (PCHD), with emphasis on current clinical utility, technical challenges, and future opportunities for implementation. Recent findings: Recent studies demonstrate that deep learning models can accurately identify arrhythmias, ventricular dysfunction, and CHD from standard ECG. Convolutional neural networks remain the dominant architecture, although transformer-based foundation models and self-supervised learning approaches are increasingly being explored. AI-ECG applications in PCHD have expanded from automated interpretation toward proactive risk stratification, including prediction of ventricular dysfunction, mortality, and sudden cardiac death risk. Additional work has investigated wearable monitoring, telemetry analysis, and integration with longitudinal clinical data. Despite promising performance, most studies remain retrospective and single-center, with limited external validation and challenges related to small datasets, physiologic heterogeneity, and age-dependent ECG variation. Summary: AI-ECG has the potential to transform PCHD by improving diagnostic accuracy, enabling earlier disease detection, and enhancing longitudinal risk assessment. Broader clinical implementation will require multicenter collaboration, prospective validation, standardized datasets, and careful attention to ethical, regulatory, and equity considerations.
- Open Access
- 17 June 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (6) , 102810
The Proteomic Profile of Adults With a Fontan Circulation
- 17 June 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (6) , 102810
Open AccessThe Proteomic Profile of Adults With a Fontan Circulation
- 21 April 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (16) , 1182-1195
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants
BACKGROUND: Survival after Fontan palliation for single ventricle heart disease has improved substantially, yet the long-term trajectory remains poorly defined. The Fontan Outcomes Network, a learning health network of 38 congenital heart centers in the United States and Canada, was established to address this gap. We report baseline characteristics and early findings from the first 1121 participants enrolled in this prospective clinical registry. METHODS: We performed a cross-sectional analysis of individuals who had undergone Fontan palliation enrolled in the Fontan Outcomes Network from August 2022 through August 2024. Demographic, clinical, imaging, procedural, and medication data were analyzed descriptively, overall and by age group (<12, 12 to <18, and ≥18 years). RESULTS: A total of 1121 participants were enrolled (mean age, 16.3±10.2 years; 471 [42%] female). Hypoplastic left heart syndrome (n=431 [38.5%]) and right ventricular–dominant anatomy (n=615 [54.9%]) were the most common primary cardiac diagnoses, especially in younger age groups. Extracardiac conduit was the most frequent Fontan type (n=749 [66.8%]). Typical Fontan-related adverse events were noted in 59% of cases (n=662), including chylous pleural effusions (n=108 [9.6%]), Fontan thrombosis (n=79 [7.1%]), and nonperioperative stroke (n=73 [6.5%]). A history of arrhythmia was present in 41.3% of patients (n=463) overall, increasing with age. Acquired comorbidities were present in 57.5% of patients (n=645), including asthma (n=132 [12%]) and sleep apnea (n=103 [9%]), with burden increasing by age. Antithrombotic medication use was nearly universal. Use of other medications varied widely by age, and included β-blockers, angiotensin-converting enzyme inhibitors, and pulmonary vasodilators. A clinical diagnosis of an anxiety disorder was present in 34.1% of patients (n=382), including 48.1% of adults (n=194 of 403), and antidepressants were prescribed in 11.8% of patients (n=132), including 23.6% of adults (n=95 of 403), highlighting the mental health needs of this population. CONCLUSIONS: The Fontan Outcomes Network includes one of the largest prospective, multi-institutional data sets of patients with Fontan circulation. These initial findings demonstrate the potential for a collaborative learning health network to advance research and quality improvement for this rare disease population.
- 21 April 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (16) , 1182-1195
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants
BACKGROUND: Survival after Fontan palliation for single ventricle heart disease has improved substantially, yet the long-term trajectory remains poorly defined. The Fontan Outcomes Network, a learning health network of 38 congenital heart centers in the United States and Canada, was established to address this gap. We report baseline characteristics and early findings from the first 1121 participants enrolled in this prospective clinical registry. METHODS: We performed a cross-sectional analysis of individuals who had undergone Fontan palliation enrolled in the Fontan Outcomes Network from August 2022 through August 2024. Demographic, clinical, imaging, procedural, and medication data were analyzed descriptively, overall and by age group (<12, 12 to <18, and ≥18 years). RESULTS: A total of 1121 participants were enrolled (mean age, 16.3±10.2 years; 471 [42%] female). Hypoplastic left heart syndrome (n=431 [38.5%]) and right ventricular–dominant anatomy (n=615 [54.9%]) were the most common primary cardiac diagnoses, especially in younger age groups. Extracardiac conduit was the most frequent Fontan type (n=749 [66.8%]). Typical Fontan-related adverse events were noted in 59% of cases (n=662), including chylous pleural effusions (n=108 [9.6%]), Fontan thrombosis (n=79 [7.1%]), and nonperioperative stroke (n=73 [6.5%]). A history of arrhythmia was present in 41.3% of patients (n=463) overall, increasing with age. Acquired comorbidities were present in 57.5% of patients (n=645), including asthma (n=132 [12%]) and sleep apnea (n=103 [9%]), with burden increasing by age. Antithrombotic medication use was nearly universal. Use of other medications varied widely by age, and included β-blockers, angiotensin-converting enzyme inhibitors, and pulmonary vasodilators. A clinical diagnosis of an anxiety disorder was present in 34.1% of patients (n=382), including 48.1% of adults (n=194 of 403), and antidepressants were prescribed in 11.8% of patients (n=132), including 23.6% of adults (n=95 of 403), highlighting the mental health needs of this population. CONCLUSIONS: The Fontan Outcomes Network includes one of the largest prospective, multi-institutional data sets of patients with Fontan circulation. These initial findings demonstrate the potential for a collaborative learning health network to advance research and quality improvement for this rare disease population.
- Open Access
Fontan Subtype, Conduit Size, and Cardiac Morphologic Factors and Their Relationship to Exercise Capacity in the Fontan Circulation: A Single Ventricle Outcomes Network (SV-ONE) Study
Background: Exercise capacity varies among individuals with a Fontan circulation. Percent predicted peak oxygen consumption (%pVO 2 ) may be influenced by ventricular morphology, Fontan subtype, and conduit characteristics, but data explaining variability in exercise capacity are limited. This study examined whether anatomical and surgical factors are associated with %pVO 2 later in life. Methods: Participants enrolled in the multicenter Single Ventricle Outcomes Network (SV-ONE) database who had cardiopulmonary exercise testing (CPET) data were included. Published reference equations were used to estimate %pVO 2 . Multivariable regression models evaluated associations between anthropometric, anatomical (diagnosis and dominant ventricle), and surgical (Fontan subtype, conduit size, and surgical era) factors and %pVO 2 . Restricted spline analyses assessed nonlinearity. Results: 561 individuals with a Fontan circulation were included in the analysis; age 20 ± 8 years, 54% male, mean %pVO 2 was 63 ± 16%. Sex and exercise modality were the strongest predictors of %pVO 2 , with females being 12% higher than males and treadmill 4.6% higher than a cycle. Age at CPET was a predictor of exercise capacity with %pVO 2 decreasing by 0.8% per year. Ventricular morphology, diagnosis, and Fontan subtype did not have a statistical association with the primary outcome. In models restricted to patients with an extracardiac conduit (n = 330), conduit diameter and area were not associated with %pVO 2 , even after indexing to body surface area. Univariable nonlinear spline analyses suggested an optimal conduit size of 18 mm for %pVO 2 , but this was not significant after body size adjustments. Conclusion: In this large multicenter cohort, surgical and anatomical features were not as important as sex, age, and body size as determinants of exercise performance in patients with a Fontan circulation. Reduced exercise capacity in this population appears to reflect progressive pathophysiological changes of the Fontan circulation rather than specific characteristics such as conduit size, ventricular morphology, or anatomy. CLINICAL PERSPECTIVE: What is new?: In this large multicenter registry study of 561 patients with a Fontan circulation, we evaluated whether early surgical and anatomical factors, including dominant ventricular morphology, underlying diagnosis, Fontan subtype, and extracardiac conduit size, are associated with exercise performance later in life as measured by percent predicted peak VO 2 . These surgical and anatomical variables explained little of the variability in exercise capacity. In contrast, demographic and testing-related factors, particularly sex, along with age and body size, were much more strongly associated with percent predicted peak VO 2 . What are the clinical implications?: Despite longstanding interest in whether Fontan configuration or dominant ventricular morphology confers superior long-term exercise capacity, this study demonstrates that these surgical and anatomical factors contribute little to exercise performance later in life. For patients with a Fontan circulation, reduced exercise capacity should not be attributed primarily to Fontan subtype or conduit size. Instead, clinical care should emphasize modifiable contributors, including regular exercise participation, preservation of skeletal muscle mass, and proactive identification and management of hemodynamic abnormalities as they evolve over time.
Open AccessFontan Subtype, Conduit Size, and Cardiac Morphologic Factors and Their Relationship to Exercise Capacity in the Fontan Circulation: A Single Ventricle Outcomes Network (SV-ONE) Study
Background: Exercise capacity varies among individuals with a Fontan circulation. Percent predicted peak oxygen consumption (%pVO 2 ) may be influenced by ventricular morphology, Fontan subtype, and conduit characteristics, but data explaining variability in exercise capacity are limited. This study examined whether anatomical and surgical factors are associated with %pVO 2 later in life. Methods: Participants enrolled in the multicenter Single Ventricle Outcomes Network (SV-ONE) database who had cardiopulmonary exercise testing (CPET) data were included. Published reference equations were used to estimate %pVO 2 . Multivariable regression models evaluated associations between anthropometric, anatomical (diagnosis and dominant ventricle), and surgical (Fontan subtype, conduit size, and surgical era) factors and %pVO 2 . Restricted spline analyses assessed nonlinearity. Results: 561 individuals with a Fontan circulation were included in the analysis; age 20 ± 8 years, 54% male, mean %pVO 2 was 63 ± 16%. Sex and exercise modality were the strongest predictors of %pVO 2 , with females being 12% higher than males and treadmill 4.6% higher than a cycle. Age at CPET was a predictor of exercise capacity with %pVO 2 decreasing by 0.8% per year. Ventricular morphology, diagnosis, and Fontan subtype did not have a statistical association with the primary outcome. In models restricted to patients with an extracardiac conduit (n = 330), conduit diameter and area were not associated with %pVO 2 , even after indexing to body surface area. Univariable nonlinear spline analyses suggested an optimal conduit size of 18 mm for %pVO 2 , but this was not significant after body size adjustments. Conclusion: In this large multicenter cohort, surgical and anatomical features were not as important as sex, age, and body size as determinants of exercise performance in patients with a Fontan circulation. Reduced exercise capacity in this population appears to reflect progressive pathophysiological changes of the Fontan circulation rather than specific characteristics such as conduit size, ventricular morphology, or anatomy. CLINICAL PERSPECTIVE: What is new?: In this large multicenter registry study of 561 patients with a Fontan circulation, we evaluated whether early surgical and anatomical factors, including dominant ventricular morphology, underlying diagnosis, Fontan subtype, and extracardiac conduit size, are associated with exercise performance later in life as measured by percent predicted peak VO 2 . These surgical and anatomical variables explained little of the variability in exercise capacity. In contrast, demographic and testing-related factors, particularly sex, along with age and body size, were much more strongly associated with percent predicted peak VO 2 . What are the clinical implications?: Despite longstanding interest in whether Fontan configuration or dominant ventricular morphology confers superior long-term exercise capacity, this study demonstrates that these surgical and anatomical factors contribute little to exercise performance later in life. For patients with a Fontan circulation, reduced exercise capacity should not be attributed primarily to Fontan subtype or conduit size. Instead, clinical care should emphasize modifiable contributors, including regular exercise participation, preservation of skeletal muscle mass, and proactive identification and management of hemodynamic abnormalities as they evolve over time.
- 15 January 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (1) , 292-301
Screening for Structural Heart Defects: A Single-Center Retrospective Cost Analysis for Fetal Echocardiography in Adults with Congenital Heart Disease
Fetal echocardiography (FE) is recommended for parents with congenital heart disease (pCHD) due to a 3–6% recurrence risk of congenital heart disease (CHD). This study aimed to evaluate the cost of FE for detecting neonatal CHD in pCHD. FE data were collected between 12/2015 and 12/2022. Parents were stratified by CHD complexity: “simple” (class I) and “complex” (class II/III). Cost analysis compared universal FE with selective FE following a positive level II screening anatomical ultrasound (SAU). Primary outcomes included the cost and number needed to screen (NNT) to detect one case of neonatal CHD. Of 419 pCHD cases, 48 were analyzed separately due to additional FE indications. Among the remaining 371 cases (73% maternal, 27% paternal; mean maternal age: 31 years), 14 postnatal CHD cases were detected (3.8%). Recurrence rates were 1.9% for simple pCHD (n = 156) and 5.1% for complex pCHD (n = 215). Universal FE increased the cost of detecting neonatal CHD. The cost per detected case was $267,157 for simple CHD (NNT = 560) and $135,125 for complex CHD (NNT = 288). The lower sensitivity of SAU reduced the cost of universal FE. In this single-center cohort, the recurrence risk of CHD in pCHD is higher than in the general population, particularly in complex cases. Universal screening in simple pCHD is costlier with high-sensitivity SAU. Targeted screening in complex pCHD may offer a better cost-to-risk ratio, highlighting the need for early detection to improve outcomes. The cost effectiveness is dependent on local SAU sensitivity rates.
- 15 January 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (1) , 292-301
Screening for Structural Heart Defects: A Single-Center Retrospective Cost Analysis for Fetal Echocardiography in Adults with Congenital Heart Disease
Fetal echocardiography (FE) is recommended for parents with congenital heart disease (pCHD) due to a 3–6% recurrence risk of congenital heart disease (CHD). This study aimed to evaluate the cost of FE for detecting neonatal CHD in pCHD. FE data were collected between 12/2015 and 12/2022. Parents were stratified by CHD complexity: “simple” (class I) and “complex” (class II/III). Cost analysis compared universal FE with selective FE following a positive level II screening anatomical ultrasound (SAU). Primary outcomes included the cost and number needed to screen (NNT) to detect one case of neonatal CHD. Of 419 pCHD cases, 48 were analyzed separately due to additional FE indications. Among the remaining 371 cases (73% maternal, 27% paternal; mean maternal age: 31 years), 14 postnatal CHD cases were detected (3.8%). Recurrence rates were 1.9% for simple pCHD (n = 156) and 5.1% for complex pCHD (n = 215). Universal FE increased the cost of detecting neonatal CHD. The cost per detected case was $267,157 for simple CHD (NNT = 560) and $135,125 for complex CHD (NNT = 288). The lower sensitivity of SAU reduced the cost of universal FE. In this single-center cohort, the recurrence risk of CHD in pCHD is higher than in the general population, particularly in complex cases. Universal screening in simple pCHD is costlier with high-sensitivity SAU. Targeted screening in complex pCHD may offer a better cost-to-risk ratio, highlighting the need for early detection to improve outcomes. The cost effectiveness is dependent on local SAU sensitivity rates.
- Open Access
Artificial Intelligence in Pediatric Electrocardiography: A Comprehensive Review
Artificial intelligence (AI) is revolutionizing healthcare by offering innovative solutions for diagnosis, treatment, and patient management. Only recently has the field of pediatric cardiology begun to explore the use of deep learning methods to analyze electrocardiogram (ECG) data, aiming to enhance diagnostic accuracy, expedite workflows, and improve patient outcomes. This review examines the current state of AI-enhanced ECG interpretation in pediatric cardiology applications, drawing insights from adult AI-ECG research given the progress in this field. It describes a broad range of AI methodologies, investigates the unique challenges inherent in pediatric ECG analysis, reviews the current state of the literature in pediatric AI-ECG, and discusses potential future directions for research and clinical practice. While AI-ECG applications have demonstrated considerable promise, widespread clinical adoption necessitates further research, rigorous validation, and careful consideration of equity, ethical, legal, and practical challenges.
Open AccessArtificial Intelligence in Pediatric Electrocardiography: A Comprehensive Review
Artificial intelligence (AI) is revolutionizing healthcare by offering innovative solutions for diagnosis, treatment, and patient management. Only recently has the field of pediatric cardiology begun to explore the use of deep learning methods to analyze electrocardiogram (ECG) data, aiming to enhance diagnostic accuracy, expedite workflows, and improve patient outcomes. This review examines the current state of AI-enhanced ECG interpretation in pediatric cardiology applications, drawing insights from adult AI-ECG research given the progress in this field. It describes a broad range of AI methodologies, investigates the unique challenges inherent in pediatric ECG analysis, reviews the current state of the literature in pediatric AI-ECG, and discusses potential future directions for research and clinical practice. While AI-ECG applications have demonstrated considerable promise, widespread clinical adoption necessitates further research, rigorous validation, and careful consideration of equity, ethical, legal, and practical challenges.
- Open Access
- 24 August 2024
- Published by Elsevier in International Journal of Cardiology Congenital Heart Disease
- Vol. 17
Novel techniques for quantifying oxygen pulse curve characteristics during cardiopulmonary exercise testing in tetralogy of fallot
- 24 August 2024
- Published by Elsevier in International Journal of Cardiology Congenital Heart Disease
- Vol. 17
Open AccessNovel techniques for quantifying oxygen pulse curve characteristics during cardiopulmonary exercise testing in tetralogy of fallot